June 2025
-
Press releaseNovartis announces expiration of Regulus Therapeutics tender offerBasel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of…
-
Press releaseNovartis announces expiration of HSR waiting period of Regulus Therapeutics tender offerBasel, June 23, 2025 – Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with…
-
Press releaseNovartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNHIn the Phase IIIB APPULSE-PNH study, adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched to Fabhalta experienced clinically meaningful improvements in hemoglobin (Hb) levels of…
-
Press releaseNovartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancerAd hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for Pluvicto™…
-
Press releaseNovartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer (EBC) patients receiving Kisqali in 1-year post-treatment analysis1Tolerability remained consistent,…
May 2025
-
Press releaseNovartis announces commencement of tender offer to acquire Regulus TherapeuticsBasel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to…
-
Story Access to Healthcare
Why advocating for your MS is so important -
Press releaseNew Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipelineNATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results…
-
Featured NewsVas Narasimhan named to 2025 TIME100 Health list
April 2025
-
Press releaseNovartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failureRegulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD…
-
Press releaseNovartis setzt die starke Dynamik fort mit zweistelligem Umsatzwachstum, robusten Margensteigerungen und mehreren Zulassungen im ersten QuartalAd-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz wuchs um +15% (kWk1, +12% USD), das operative Kernergebnis1 verbesserte sich um +27% (kWk, +23% USD)Das Umsatzwachstum beruhte auf…
-
Press releaseNovartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1Ad hoc announcement pursuant to Art. 53 LRNet sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto…